Cargando…

Sodium-glucose co-transporter 1 (SGLT1) differentially regulates gluconeogenesis and GLP-1 receptor (GLP-1R) expression in different diabetic rats: a preliminary validation of the hypothesis of “SGLT1 bridge” as an indication for “surgical diabetes”

BACKGROUND: Sodium-glucose co-transporter 1 (SGLT1) may play a synergistic role in gluconeogenesis (GNG) and glucagon-like peptide-1 (GLP-1) expression. We proposed the hypothesis of a “SGLT1 bridge” as an indication for “surgical diabetes” that was preliminary validated in the present study. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Hengliang, Cai, Huajie, Wang, Xiaokun, Chen, Tao, Zhen, Chaohui, Zhang, Zhenzhan, Ruan, Xiaojiao, Li, Guoxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096370/
https://www.ncbi.nlm.nih.gov/pubmed/35571394
http://dx.doi.org/10.21037/atm-22-1769
_version_ 1784705962567794688
author Zhu, Hengliang
Cai, Huajie
Wang, Xiaokun
Chen, Tao
Zhen, Chaohui
Zhang, Zhenzhan
Ruan, Xiaojiao
Li, Guoxin
author_facet Zhu, Hengliang
Cai, Huajie
Wang, Xiaokun
Chen, Tao
Zhen, Chaohui
Zhang, Zhenzhan
Ruan, Xiaojiao
Li, Guoxin
author_sort Zhu, Hengliang
collection PubMed
description BACKGROUND: Sodium-glucose co-transporter 1 (SGLT1) may play a synergistic role in gluconeogenesis (GNG) and glucagon-like peptide-1 (GLP-1) expression. We proposed the hypothesis of a “SGLT1 bridge” as an indication for “surgical diabetes” that was preliminary validated in the present study. METHODS: We selected nonobese diabetic Goto-Kakizaki (GK) rats and Zuker diabetic fat (ZDF) rats to represent advanced and early diabetes, respectively. Based on glucose gavage with or without SGLT1 inhibitor phlorizin, the rats were divided into 4 groups: Gk-Glu, GK-P, ZDF-Glu, and ZDF-P. The expressions of SGLT1, GLP-1 receptor (GLP-1R), glucose-6 phosphatase (G6Pase), and phosphoenolpyruvate carboxykinase-1 (Pck1) were determined by immunohistochemistry (IHC) or quantitative reverse transcription polymerase chain reaction (RT-qPCR), and the effects of phlorizin were analyzed. RESULTS: Glucose tolerance was worse in GK rats and the homeostasis model assessment-insulin resistance (HOMA-IR) was higher in ZDF rats, indicating different pathophysiological conditions between the different diabetic rats. GK rats showed higher activity of duodenal SGLT1 (P=0.022) and jejunal SGLT1 mRNA expression (P=0.000) and lower SGLT1 mRNA expression in the liver (P=0.000) and pancreas (P=0.000). Phlorizin effectively inhibited the activity of duodenal SGLT1 in both GK rats (P=0.000) and ZDF rats (P=0.000). In ZDF rats, the expression of GLP-1R mRNA was downregulated in the jejunum (P=0.001) and upregulated in the pancreas (P=0.021) by phlorizin, but there were no regulatory effects on GLP-1R mRNA in the jejunum and pancreas of GK rats. As for the regulatory effects on GNG, phlorizin upregulated Pck1 mRNA in the duodenum (P=0.000) and the jejunum (P=0.038), whereas it downregulated hepatic G6Pase mRNA in ZDF rats (P=0.005) and Pck1 mRNA expression in GK rats (P=0.001), suggesting that SGLT1 inhibitor may have upregulated intestinal GNG in ZDF rats and downregulated hepatic GNG in both ZDF and GK rats. CONCLUSIONS: SGLT1 showed synergistic regulatory effects on the entero-insular axis (EIA) and the gut-brain-liver axis (GBLA), preliminarily validating the hypothesis of a “SGLT1 bridge”. The distinct expression of SGLT1 and its differentially regulatory effects on diabetic rats with different pathophysiological conditions may provide probable potential indications involved in the “Surgical Diabetes” that is supposed as the inclusion for diabetic surgery.
format Online
Article
Text
id pubmed-9096370
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-90963702022-05-13 Sodium-glucose co-transporter 1 (SGLT1) differentially regulates gluconeogenesis and GLP-1 receptor (GLP-1R) expression in different diabetic rats: a preliminary validation of the hypothesis of “SGLT1 bridge” as an indication for “surgical diabetes” Zhu, Hengliang Cai, Huajie Wang, Xiaokun Chen, Tao Zhen, Chaohui Zhang, Zhenzhan Ruan, Xiaojiao Li, Guoxin Ann Transl Med Original Article BACKGROUND: Sodium-glucose co-transporter 1 (SGLT1) may play a synergistic role in gluconeogenesis (GNG) and glucagon-like peptide-1 (GLP-1) expression. We proposed the hypothesis of a “SGLT1 bridge” as an indication for “surgical diabetes” that was preliminary validated in the present study. METHODS: We selected nonobese diabetic Goto-Kakizaki (GK) rats and Zuker diabetic fat (ZDF) rats to represent advanced and early diabetes, respectively. Based on glucose gavage with or without SGLT1 inhibitor phlorizin, the rats were divided into 4 groups: Gk-Glu, GK-P, ZDF-Glu, and ZDF-P. The expressions of SGLT1, GLP-1 receptor (GLP-1R), glucose-6 phosphatase (G6Pase), and phosphoenolpyruvate carboxykinase-1 (Pck1) were determined by immunohistochemistry (IHC) or quantitative reverse transcription polymerase chain reaction (RT-qPCR), and the effects of phlorizin were analyzed. RESULTS: Glucose tolerance was worse in GK rats and the homeostasis model assessment-insulin resistance (HOMA-IR) was higher in ZDF rats, indicating different pathophysiological conditions between the different diabetic rats. GK rats showed higher activity of duodenal SGLT1 (P=0.022) and jejunal SGLT1 mRNA expression (P=0.000) and lower SGLT1 mRNA expression in the liver (P=0.000) and pancreas (P=0.000). Phlorizin effectively inhibited the activity of duodenal SGLT1 in both GK rats (P=0.000) and ZDF rats (P=0.000). In ZDF rats, the expression of GLP-1R mRNA was downregulated in the jejunum (P=0.001) and upregulated in the pancreas (P=0.021) by phlorizin, but there were no regulatory effects on GLP-1R mRNA in the jejunum and pancreas of GK rats. As for the regulatory effects on GNG, phlorizin upregulated Pck1 mRNA in the duodenum (P=0.000) and the jejunum (P=0.038), whereas it downregulated hepatic G6Pase mRNA in ZDF rats (P=0.005) and Pck1 mRNA expression in GK rats (P=0.001), suggesting that SGLT1 inhibitor may have upregulated intestinal GNG in ZDF rats and downregulated hepatic GNG in both ZDF and GK rats. CONCLUSIONS: SGLT1 showed synergistic regulatory effects on the entero-insular axis (EIA) and the gut-brain-liver axis (GBLA), preliminarily validating the hypothesis of a “SGLT1 bridge”. The distinct expression of SGLT1 and its differentially regulatory effects on diabetic rats with different pathophysiological conditions may provide probable potential indications involved in the “Surgical Diabetes” that is supposed as the inclusion for diabetic surgery. AME Publishing Company 2022-04 /pmc/articles/PMC9096370/ /pubmed/35571394 http://dx.doi.org/10.21037/atm-22-1769 Text en 2022 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Zhu, Hengliang
Cai, Huajie
Wang, Xiaokun
Chen, Tao
Zhen, Chaohui
Zhang, Zhenzhan
Ruan, Xiaojiao
Li, Guoxin
Sodium-glucose co-transporter 1 (SGLT1) differentially regulates gluconeogenesis and GLP-1 receptor (GLP-1R) expression in different diabetic rats: a preliminary validation of the hypothesis of “SGLT1 bridge” as an indication for “surgical diabetes”
title Sodium-glucose co-transporter 1 (SGLT1) differentially regulates gluconeogenesis and GLP-1 receptor (GLP-1R) expression in different diabetic rats: a preliminary validation of the hypothesis of “SGLT1 bridge” as an indication for “surgical diabetes”
title_full Sodium-glucose co-transporter 1 (SGLT1) differentially regulates gluconeogenesis and GLP-1 receptor (GLP-1R) expression in different diabetic rats: a preliminary validation of the hypothesis of “SGLT1 bridge” as an indication for “surgical diabetes”
title_fullStr Sodium-glucose co-transporter 1 (SGLT1) differentially regulates gluconeogenesis and GLP-1 receptor (GLP-1R) expression in different diabetic rats: a preliminary validation of the hypothesis of “SGLT1 bridge” as an indication for “surgical diabetes”
title_full_unstemmed Sodium-glucose co-transporter 1 (SGLT1) differentially regulates gluconeogenesis and GLP-1 receptor (GLP-1R) expression in different diabetic rats: a preliminary validation of the hypothesis of “SGLT1 bridge” as an indication for “surgical diabetes”
title_short Sodium-glucose co-transporter 1 (SGLT1) differentially regulates gluconeogenesis and GLP-1 receptor (GLP-1R) expression in different diabetic rats: a preliminary validation of the hypothesis of “SGLT1 bridge” as an indication for “surgical diabetes”
title_sort sodium-glucose co-transporter 1 (sglt1) differentially regulates gluconeogenesis and glp-1 receptor (glp-1r) expression in different diabetic rats: a preliminary validation of the hypothesis of “sglt1 bridge” as an indication for “surgical diabetes”
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096370/
https://www.ncbi.nlm.nih.gov/pubmed/35571394
http://dx.doi.org/10.21037/atm-22-1769
work_keys_str_mv AT zhuhengliang sodiumglucosecotransporter1sglt1differentiallyregulatesgluconeogenesisandglp1receptorglp1rexpressionindifferentdiabeticratsapreliminaryvalidationofthehypothesisofsglt1bridgeasanindicationforsurgicaldiabetes
AT caihuajie sodiumglucosecotransporter1sglt1differentiallyregulatesgluconeogenesisandglp1receptorglp1rexpressionindifferentdiabeticratsapreliminaryvalidationofthehypothesisofsglt1bridgeasanindicationforsurgicaldiabetes
AT wangxiaokun sodiumglucosecotransporter1sglt1differentiallyregulatesgluconeogenesisandglp1receptorglp1rexpressionindifferentdiabeticratsapreliminaryvalidationofthehypothesisofsglt1bridgeasanindicationforsurgicaldiabetes
AT chentao sodiumglucosecotransporter1sglt1differentiallyregulatesgluconeogenesisandglp1receptorglp1rexpressionindifferentdiabeticratsapreliminaryvalidationofthehypothesisofsglt1bridgeasanindicationforsurgicaldiabetes
AT zhenchaohui sodiumglucosecotransporter1sglt1differentiallyregulatesgluconeogenesisandglp1receptorglp1rexpressionindifferentdiabeticratsapreliminaryvalidationofthehypothesisofsglt1bridgeasanindicationforsurgicaldiabetes
AT zhangzhenzhan sodiumglucosecotransporter1sglt1differentiallyregulatesgluconeogenesisandglp1receptorglp1rexpressionindifferentdiabeticratsapreliminaryvalidationofthehypothesisofsglt1bridgeasanindicationforsurgicaldiabetes
AT ruanxiaojiao sodiumglucosecotransporter1sglt1differentiallyregulatesgluconeogenesisandglp1receptorglp1rexpressionindifferentdiabeticratsapreliminaryvalidationofthehypothesisofsglt1bridgeasanindicationforsurgicaldiabetes
AT liguoxin sodiumglucosecotransporter1sglt1differentiallyregulatesgluconeogenesisandglp1receptorglp1rexpressionindifferentdiabeticratsapreliminaryvalidationofthehypothesisofsglt1bridgeasanindicationforsurgicaldiabetes